On May 27, 2021, Innovation Pharmaceuticals announced that patient enrollment in the Companyﾒs 120-patient, Phase 2 clinical trial of Brilacidin for COVID-19 had reached 90 percent and that the Company anticipated full enrollment in two weeks.

Brilacidin is the only non-peptidic defensin-mimetic drug candidate currently in a clinical trial as a treatment for SARS-CoV-2, the coronavirus responsible for COVID-19.